Menu Search
Equities

Baxter International Inc

BTL:FRA

Baxter International Inc

Actions
  • Price (EUR)65.91
  • Today's Change0.04 / 0.06%
  • Shares traded0.00
  • 1 Year change-18.51%
  • Beta0.6377
Data delayed at least 15 minutes, as of Jan 18 2021 08:16 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.

  • Revenue in USD (TTM)11.53bn
  • Net income in USD733.00m
  • Incorporated1931
  • Employees50.00k
  • Location
    Baxter International Inc1 Baxter PkwyDEERFIELD 60015-4625United StatesUSA
  • Phone+1 (847) 948-2000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.baxter.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		BAX:NYQ since
announced		Transaction
value
Omnicell IncRumoured08 Dec 202008 Dec 2020Rumoured2.92%--
Data delayed at least 15 minutes, as of Jan 15 2021 21:10 GMT.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.